Hedgehogs, flies, wnts and MYCs: The time has come for many things in medulloblastoma

Journal of Clinical Oncology

Volumn 29, Issue 11, 2011, Pages 1395-1398

  Monje, Michelle ^a   Beachy, Philip A ^a   Fisher, Paul G ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CALBINDIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MOLECULAR MARKER; MYC PROTEIN; NEUROTROPHIN 3 RECEPTOR; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CELL PROLIFERATION; CHILDHOOD CANCER; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 8Q; CLINICAL PRACTICE; COGNITIVE DEFECT; COPY NUMBER VARIATION; EMBRYO DEVELOPMENT; ENDOCRINE DISEASE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HEARING LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; ISOCHROMOSOME; MEDULLOBLASTOMA; MOLECULAR BIOLOGY; NERVE FIBER; NEUROPATHY; ONCOGENE C MYC; PRIORITY JOURNAL; REVIEW; SECOND CANCER; SEIZURE; SIGNAL TRANSDUCTION; STROKE; SUBARACHNOID SPACE;

CEREBELLAR NEOPLASMS; CHILD; GENE EXPRESSION PROFILING; HEDGEHOG PROTEINS; HUMANS; MEDULLOBLASTOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; WNT PROTEINS;

EID: 79955010717     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.0547     Document Type: Review

References (37)

1. Central Brain Tumor Registry of the United States: 2010 statistical report tables: Primary brain and central nervous system tumors diagnosed in the United States in 2004-2006. http://www.cbtrus.org/2007-2008/2007-20081 html
2. Gurney J, Smith MA, Bunin GR: CNS and miscellaneous intracranial and intraspinal neoplasms, in Ries LAG, Smith MA, Gurney JG, et al (eds): Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD, National Cancer Institute, NIH Publication 99-4649, 1999, pp 51-63
3. Tait DM, Thornton-Jones H, Bloom HJ, et al: Adjuvant chemotherapy for medulloblastoma: The first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26:464-469, 1990 (Pubitemid 20209976)
4. Evans AE, Jenkin RD, Sposto R, et al: The treatment of medulloblastoma: Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72:572-582, 1990 (Pubitemid 20113683)
5. Krischer JP, Ragab AH, Kun L, et al: Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma: A Pediatric Oncology Group study. J Neurosurg 74:905-909, 1991
6. Packer RJ, Goldwein J, Nicholson HS, et al: Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 17:2127-2136, 1999 (Pubitemid 29318845)
7. Packer RJ, Gajjar A, Vezina G, et al: Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24:4202-4208, 2006 (Pubitemid 46622300)
8. Mulhern RK, Kepner JL, Thomas PR, et al: Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: A Pediatric Oncology Group study. J Clin Oncol 16:1723-1728, 1998
9. Armstrong GT, Liu Q, Yasui Y, et al: Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 101:946-958, 2009
10. Packer RJ, Gurney JG, Punyko JA, et al: Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: Childhood cancer survivor study. J Clin Oncol 21:3255-3261, 2003 (Pubitemid 46606258)
11. Chang CH, Housepian EM, Herbert C Jr: An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93:1351-1359, 1969
12. Chatty EM, Earle KM: Medulloblastoma: A report of 201 cases with emphasis on the relationship of histologic variants to survival. Cancer 28:977-983, 1971
13. Giangaspero F, Rigobello L, Badiali M, et al: Large-cell medulloblastomas: A distinct variant with highly aggressive behavior. Am J Surg Pathol 16:687-693, 1992
14. Eberhart CG, Kepner JL, Goldthwaite PT, et al: Histopathologic grading of medulloblastomas: A Pediatric Oncology Group study. Cancer 94:552-560, 2002 (Pubitemid 34081387)
15. McManamy CS, Lamont JM, Taylor RE, et al: Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 62:627-632, 2003 (Pubitemid 36682635)
16. Gilbertson R, Wickramasinghe C, Hernan R, et al: Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85:705-712, 2001 (Pubitemid 32929469)
17. Brown HG, Kepner JL, Perlman EJ, et al: "Large cell/anaplastic" medulloblastomas: A Pediatric Oncology Group Study. J Neuropathol Exp Neurol 59:857-865, 2000
18. Clifford SC, Lusher ME, Lindsey JC, et al: Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 5:2666-2670, 2006
19. Kool M, Koster J, Bunt J, et al: Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3:e3088, 2008
20. Fattet S, Haberler C, Legoix P, et al: Beta-catenin status in paediatric medulloblastomas: Correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 218:86-94, 2009
21. Kim JY, Sutton ME, Lu DJ, et al: Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 59:711-719, 1999 (Pubitemid 29076072)
22. Grotzer MA, Janss AJ, Phillips PC, et al: Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. Klin Padiatr 212:196-199, 2000 (Pubitemid 30650554)
23. Ellison DW, Onilude OE, Lindsey JC, et al: Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23:7951-7957, 2005 (Pubitemid 46657395)
24. Thompson MC, Fuller C, Hogg TL, et al: Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24:1924-1931, 2006 (Pubitemid 46638992)
25. Pelc K, Vincent S, Ruchoux MM, et al: Calbindin-d(28k): A marker of recurrence for medulloblastomas. Cancer 95:410-419, 2002
26. Gajjar A, Hernan R, Kocak M, et al: Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22:984-993, 2004 (Pubitemid 41095029)
27. Scheurlen WG, Schwabe GC, Joos S, et al: Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 16:2478-2485, 1998 (Pubitemid 28309044)
28. Lamont JM, McManamy CS, Pearson AD, et al: Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10:5482-5493, 2004 (Pubitemid 39100486)
29. Eberhart CG, Kratz J, Wang Y, et al: Histopathological and molecular prognostic markers in medulloblastoma: C-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63:441-449, 2004 (Pubitemid 38669665)
30. Pomeroy SL, Tamayo P, Gaasenbeek M, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436-442, 2002 (Pubitemid 34100955)
31. Ellison DW, Kocak M, Dalton J, et al: Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29:1400-1407, 2011
32. Cho Y-J, Tsherniak A, Tamayo P, et al: Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29:1424-1430, 2011
33. Tamayo P, Cho Y-J, Tsherniak A, et al: Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol 29:1415-1423, 2011
34. Northcott PA, Korshunov A, Witt H, et al: Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29:1408-1414, 2011
35. Kessler JD, Hasegawa H, Brun SN, et al: N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes Dev 23:157-170, 2009
36. Carroll L: Through the looking glass and what Alice found there, in The Annotated Alice. New York, NY, Norton, 2000, pp 129-271
37. Gibson P, Tong Y, Robinson G, et al: Subtypes of medulloblastoma have distinct developmental origins. Nature 468:1095-1099, 2010